Alzheimer disease 13

Summary

Alzheimer disease 13 (MONDO:0012630) is a disease and 2 clinical trials. A subtype of early-onset autosomal dominant Alzheimer disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	Alzheimer disease 13
Mondo ID	MONDO:0012630
MeSH	C567000
OMIM	611152
DOID	DOID:0110046
UMLS	C1970147
MedGen	370835
GARD	0016517
Is cancer (heuristic)	no

Also known as: AD13 · Alzheimer disease 13 · Alzheimer disease-13 · Alzheimer’s disease 13 · Alzheimer’s disease type 13

Disease family

This is a subtype of early-onset autosomal dominant Alzheimer disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal dominant disease › early-onset autosomal dominant Alzheimer disease › Alzheimer disease 13

Related subtypes (13): Alzheimer disease type 1, Alzheimer disease 5, Alzheimer disease without neurofibrillary tangles, Alzheimer disease, familial early-onset, with coexisting amyloid and prion pathology, Alzheimer disease 6, Alzheimer disease 7, Alzheimer disease 4, Alzheimer disease 8, Alzheimer disease 3, Alzheimer disease 10, Alzheimer disease 11, Alzheimer disease 12, Alzheimer disease 14

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05637801	Not specified	ACTIVE_NOT_RECRUITING	A Pivotal Study of Sensory Stimulation in Alzheimer’s Disease (HOPE Study)
NCT04100889	Not specified	WITHDRAWN	A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer’s Disease